313,000 Shares in Ocular Therapeutix, Inc. $OCUL Purchased by Prescott Group Capital Management L.L.C.

Prescott Group Capital Management L.L.C. acquired a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 313,000 shares of the biopharmaceutical company’s stock, valued at approximately $3,800,000. Prescott Group Capital Management L.L.C. owned approximately 0.15% of Ocular Therapeutix as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of the business. Citigroup Inc. grew its stake in shares of Ocular Therapeutix by 574.4% during the 3rd quarter. Citigroup Inc. now owns 673,348 shares of the biopharmaceutical company’s stock valued at $7,871,000 after purchasing an additional 573,504 shares during the period. Vanguard Group Inc. grew its stake in shares of Ocular Therapeutix by 9.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,163,240 shares of the biopharmaceutical company’s stock valued at $107,118,000 after purchasing an additional 771,065 shares during the period. Cantor Fitzgerald L. P. bought a new stake in shares of Ocular Therapeutix during the 3rd quarter valued at about $2,360,000. Avoro Capital Advisors LLC grew its stake in shares of Ocular Therapeutix by 38.5% during the 3rd quarter. Avoro Capital Advisors LLC now owns 10,250,000 shares of the biopharmaceutical company’s stock valued at $119,822,000 after purchasing an additional 2,850,000 shares during the period. Finally, Rhenman & Partners Asset Management AB bought a new stake in shares of Ocular Therapeutix during the 3rd quarter valued at about $2,361,000. 59.21% of the stock is currently owned by institutional investors.

Ocular Therapeutix Stock Up 0.5%

OCUL stock opened at $8.03 on Thursday. Ocular Therapeutix, Inc. has a twelve month low of $6.23 and a twelve month high of $16.44. The company has a quick ratio of 14.73, a current ratio of 14.81 and a debt-to-equity ratio of 0.12. The stock has a market cap of $1.76 billion, a P/E ratio of -5.50 and a beta of 0.93. The business’s 50-day moving average price is $8.86 and its 200-day moving average price is $10.34.

Insider Buying and Selling

In related news, Director Richard L. Md Lindstrom acquired 60,229 shares of the stock in a transaction dated Friday, February 20th. The shares were purchased at an average cost of $7.66 per share, with a total value of $461,354.14. Following the transaction, the director directly owned 246,933 shares in the company, valued at approximately $1,891,506.78. This represents a 32.26% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Pravin Dugel sold 20,056 shares of Ocular Therapeutix stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $8.28, for a total value of $166,063.68. Following the transaction, the insider directly owned 3,013,022 shares in the company, valued at approximately $24,947,822.16. The trade was a 0.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 31,192 shares of company stock valued at $256,374 in the last 90 days. Corporate insiders own 2.30% of the company’s stock.

Analyst Ratings Changes

OCUL has been the subject of a number of recent research reports. Needham & Company LLC restated a “buy” rating and set a $18.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, May 5th. Jefferies Financial Group restated a “buy” rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. Chardan Capital restated a “buy” rating and set a $21.00 price target on shares of Ocular Therapeutix in a research note on Wednesday, February 18th. HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of Ocular Therapeutix in a research note on Monday, April 13th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $30.00 price target on shares of Ocular Therapeutix in a research note on Wednesday, May 6th. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $23.78.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.